Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers - Reuters

Reuters | Feb. 4, 2025, 1:23 a.m. | Original
Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers Reuters
Amundi posts in-line Q4 inflows on risk-averse products - Reuters Publicis forecasts slower 2025, remains confident on outperformance - Reuters